Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
View Patent ↗GnRH receptor antagonists are disclosed which have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure, wherein R 1a , R 1b , R 1c , R 1d , R 2 , R 2a , and A are as defined herein, including stereoisomers, esters, solvates and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.
1. A compound having the following structure (I):
or a stereoisomer or pharmaceutically acceptable salt thereof,
wherein:
A is pyridyl, phenyl or quinolinyl substituted with 0-5 R 4 ;
R 1a is H, halogen, C 1-4 alkyl, alkoxy or trifluoromethyl;
R 1b and R 1c are the same or different and are independently H, halogen, hydroxy, haloC 1-4 alkyl, —C 1-6 alkyl-(R 5 ) p , —O—C 1-6 alkyl-(R 5 ) p , —C 1-6 alkyl-O—C 1-6 alkyl-(R 5 ) p , —NR 7 —C 1-6 alkyl-(R 5 ) p , or —S(O) m —C 1-6 alkyl-(R 5 ) p ;
R 1d is Cl, F, methyl, CF 3 or cyano;
R 2 is —C 1-4 alkyl-(R 5 ) p ;
R 2a is phenyl substituted with 0-4 R 3 , heteroaryl substituted with 0-4 R 3 , C 1-6 alkyl substituted with 0-4 R 3 , aryl-C 1-4 alkyl substituted with 0-4 R 3 , or heteroaryl-C 1-4 alkyl substituted with 0-4 R 3 , wherein R 2a is acyclic or comprises phenyl, pyridyl or quinolinyl;
R 3 at each occurrence is independently halogen, cyano, halo-C 1-4 alkyl, R 5 , —C 1-6 alkyl-(R 5 ) p , —C 1-6 alkyl-O—C 1-6 alkyl-(R 5 ) p , —O—C 1-6 alkyl-(R 5 ) p , —NR 7 —C 1-6 alkyl-(R 5 ) p , —S(O) m —C 1-6 alkyl-(R 5 ) p , —O—C 1-6 alkyl-NR 7 —C 1-6 alkyl-(R 5 ) p , heterocycle-(R 5 ) p , wherein R 3 is acyclic or comprises pyridyl or quinolinyl;
R 4 at each occurrence is independently halogen, C 1-6 alkyl, haloC 1-4 alkyl, C 1-6 alkoxy, hydroxy, cyano, thioC 1-6 alkyl, or —C(O)NR 7 R 8 , wherein R 4 is acyclic;
R 5 at each occurrence is independently H, hydroxy, —OC(O)—C 1-6 alkyl, —OC(O)O—C 1-6 alkyl, —OC(O)—C 1-6 alkyl-NR 7 R 8 , —COOR 6 , —C(O)NR 7 R 8 , —NR 7 C(O)NR 7 R 8 , —S(O) 2 NR 9 R 9 , —S(O) m —C 1-4 alkyl, —NR 7 R 8 , C 1-6 alkoxy, —O-heterocycle, or heterocycle wherein said heterocycle and said —O-heterocycle are substituted with 0-4 groups selected from halogen, C 1-6 alkyl, C 1-4 -haloalkyl, hydroxy, oxo, thio, —NH 2 , —S(O) 2 C 1-4 alkyl and —COOH, wherein R 5 is acyclic or comprises pyridyl or quinolinyl;
R 6 at each occurrence is independently H, C 1-4 alkyl, C 1-4 alkyl-O—C(O)—C 1-6 alkyl, or C 1-4 alkyl-O—C(O)—O—C 1-6 alkyl;
R 7 at each occurrence is independently H, C 1-4 alkyl, hydroxy, or heterocycle where said heterocycle is substituted with 0-4 groups selected from halogen, C 1-6 alkyl, hydroxy, keto, —NH 2 and —COOH, wherein R 7 is acyclic or comprises phenyl, pyridyl or quinooinyl;
R 8 at each occurrence is independently H, C 1-4 alkyl, haloC 1-4 alkyl, —C(O)—C 1-4 alkyl, —C(O)-haloC 1-4 alkyl, —S(O) m -haloC 1-4 alkyl or —S(O) m —C 1-4 alkyl;
R 9 at each occurrence is independently H, C 1-4 alkyl, or —C(O)C 1-4 alkyl;
m is 0-2; and
p at each occurrence is independently 1-3.
2. A compound of claim 1 having the following structure (Ia):
or a stereoisomer or pharmaceutically acceptable salt thereof,
wherein:
A is pyridyl, phenyl or quinolinyl substituted with 0-4 R 4 ,
R 1a is H, halogen, alkyl, alkoxy or trifluoromethyl;
R 1b and R 1c are the same or different and are independently H, halogen, hydroxy, haloC 1-4 alkyl, —C 1-6 alkyl-(R 5 ) p , —O—C 1-6 alkyl-(R 5 ) p , —C 1-6 alkyl-O—C 1-6 alkyl-(R 5 ) p , —NR 7 —C 1-6 alkyl-(R 5 ) p , or —S(O) m —C 1-6 alkyl-(R 5 ) p ;
R 1d is Cl, methyl, CF 3 or cyano;
R 2 is C 1-4 alkyl-(R 5 ) p ;
R 3 at each occurrence is independently halogen, haloC 1-4 alkyl, hydroxy, —C 1-6 alkyl-(R 5 ) p , —C 1-6 alkyl-O—C 1-6 alkyl-(R 5 ) p , —O—C 1-6 alkyl-(R 5 ) p , —NR 7 —C 1-6 alkyl-(R 5 ) p , —S(O) m —C 1-6 alkyl-(R 5 ) p , —CO 2 R 6 , —C(O)NR 7 R 8 , wherein R 3 is acyclic;
R 4 at each occurrence is independently halogen, alkyl, haloC 1-4 alkyl, C 1-4 alkoxy, hydroxy, cyano, thioC 1-4 alkyl, or —C(O)NR 7 R 8 , wherein R 4 is acyclic;
R 5 at each occurrence is independently H, hydroxy, —OC(O)—C 1-6 alkyl, —OC(O)O—C 1-6 alkyl, —OC(O)—C 1-6 alkyl-NR 7 R 8 , —COOR 6 , —C(O)NR 7 R 8 , —S(O) 2 NR 9 R 9 , —S(O) m C 1-4 alkyl, —NR 7 R 8 , C 1-6 alkoxy, wherein R 5 is acyclic;
R 6 at each occurrence is independently H, C 1-4 alkyl, C 1-4 alkyl-O—C(O)—C 1-6 alkyl, or C 1-4 alkyl-O—C(O)—O—C 1-6 alkyl;
R 7 is H, C 1-4 alkyl or hydroxy, wherein R 7 is acyclic;
R 8 is H, C 1-4 alkyl, —C(O)—C 1-4 alkyl, —C(O)NR 7 —C 1-4 alkyl, or —S(O) m —C 1-4 alkyl;
R 9 at each occurrence is independently H, C 1-4 alkyl, or —C(O)C 1-4 alkyl;
m is 0-2;
n is 0-4; and
p at each occurrence is independently 1-3.
3. A compound of claim 1 wherein A is pyridyl substituted with 0-4 R 4 .
4. A compound of claim 3 wherein A is 2-pyridyl substituted with 0-4 R 4 .
5. A compound of claim 3 wherein A is 3-pyridyl substituted with 0-4 R 4 .
6. A compound of claim 1 wherein A is phenyl substituted with 0-4 R 4 .
7. A compound of claim 1 wherein A is quinolinyl substituted with 0-4 R 4 .
8. A compound of claim 1 wherein R 1a and R 1c are H.
9. A compound of claim 1 wherein R 1b is —C 1-6 alkyl-(R 5 ) p or —O—C 1-6 alkyl-(R 5 ) p , p is 1, and R 5 is H, hydroxy or COOR 6 .
10. A compound of claim 1 wherein R 2a is phenyl substituted with 1 or 2 R 3 , wherein one of R 3 is —O—C 1-6 alkyl-(R 5 ) p , p is 1, and R 5 is H hydroxy or COOR 6 .
11. A compound of claim 1 wherein R 3 is —C 1-6 alkyl-(R 5 ) p , —C 1-6 alkyl-O—C 1-6 alkyl-(R 5 ) p or —O—C 1-6 alkyl-(R 5 ) p .
12. A compound of claim 1 wherein the compound is 3-(2-{[4-Chloro-3-(6-chloro-4-methyl-pyridin-3-yl)-benzoyl]-methyl-amino}-phenoxy)-propionic acid, 3-(2-{[4-Chloro-3-(4-methyl-6-trifluoromethyl-pyridin-3-yl)-benzoyl]-methyl-amino}-phenoxy)-propionic acid, 3-(2-{[4-Chloro-3-(4-cyano-6-trifluoromethyl-pyridin-3-yl)-benzoyl]-methyl-amino}-phenoxy)-propionic acid, 3-(2-{[4-Chloro-3-(4-methyl-6-trifluoromethyl-pyridin-3-yl)-benzoyl]-methyl-amino}-3-methyl-phenoxy)-propionic acid, 3-(2-{[4-Chloro-3-(6-cyano-4-methyl-pyridin-3-yl)-benzoyl]-methyl-amino}-3-methyl-phenoxy)-propionic acid, 3-(2-{[4-Chloro-3-(4-cyano-6-trifluoromethyl-pyridin-3-yl)-benzoyl]-methyl-amino}-3-methyl-phenoxy)-propionic acid, 4-(2-{[4-Chloro-3-(4-cyano-6-trifluoromethyl-pyridin-3-yl)-benzoyl]-methyl-amino}-phenyl)-butyric acid, 2-{[4-Chloro-5-(4-cyano-6-trifluoromethyl-pyridin-3-yl)-2-methoxy-benzoyl]-methyl-amino}-benzoic acid methyl ester, 4-Chloro-5-(4-cyano-6-trifluoromethyl-pyridin-3-yl)-N-(2-fluoro-6-methoxy-phenyl)-2-methoxy-N-methyl-benzamide, or a pharmaceutically acceptable salt thereof.
13. A compound of claim 1 wherein the compound is 4-{5-Chloro-4-(4-cyano-6-trifluoromethyl-pyridin-3-yl)-2-[(2-methoxy-6-methyl-phenyl)-methyl-carbamoyl]-phenoxy}-butyric acid, 3-{5-Chloro-4-(4-cyano-6-trifluoromethyl-pyridin-3-yl)-2-[(2-methoxy-6-methyl-phenyl)-methyl-carbamoyl]-phenoxy}-propionic acid, 4-{5-Chloro-4-(4-cyano-6-trifluoromethyl-pyridin-3-yl)-2-[(2-methoxy-phenyl)-methyl-carbamoyl]-phenoxy}-butyric acid, 4-[5-Chloro-2-[(5-chloro-2-methoxy-phenyl)-methyl-carbamoyl]-4-(4-cyano-6-trifluoromethyl-pyridin-3-yl)-phenoxy]-butyric acid, 2-{[2-(3-Carboxy-propoxy)-4-chloro-5-(4-cyano-6-trifluoromethyl-pyridin-3-yl)-benzoyl]-methyl-amino}-benzoic acid methyl ester, 4-{5-Chloro-4-(4-cyano-6-trifluoromethyl-pyridin-3-yl)-2-[methyl-(2-oxazol-5-yl-phenyl)-carbamoyl]-phenoxy}-butyric acid, 4-{5-Chloro-4-(4-cyano-6-trifluoromethyl-pyridin-3-yl)-2-[(2-fluoro-6-methoxy-phenyl)-methyl-carbamoyl]-phenoxy}-butyric acid, 4-Chloro-5-(4-cyano-6-trifluoromethyl-pyridin-3-yl)-N-(2-methoxy-phenyl)-N-methyl-2-[3-(2H-tetrazol-5-yl)-propoxy]-benzamide, 4-Chloro-3-(4-cyano-6-trifluoromethyl-pyridin-3-yl)-N-methyl-N-{2-[2-(1H-tetrazol-5-yl)-ethoxy]-phenyl}-benzamide, or a pharmaceutically acceptable salt thereof.
14. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.
15. A method for treating a condition in a subject in need thereof, wherein said condition is endometriosis, uterine fibroids, polycystic ovarian disease, dysmenorrhea, dyspareunia, menorrhagia, premature ovarian failure due to chemotherapy or early menopause, hirsutism, precocious puberty, gonadal steroid-dependent neoplasia such as cancers of the prostate, breast and ovary, gonadotrophe pituitary adenomas, adenomyosis, premenstrual syndrome, benign prostatic hypertrophy, or infertility, comprising administering to the subject an effective amount of the pharmaceutical composition of claim 14 .
16. A method of claim 15 wherein the condition is endometriosis, dysmenorrhea, polycystic ovarian disease or uterine fibroids.
17. A method of claim 15 wherein the condition is benign prostatic hypertrophy, lower urinary tract symptoms, myoma of the uterus, prostatic cancer, uterine cancer, breast cancer or pituitary gonadotroph adenomas.